GPX4 and nasopharyngeal carcinoma: GPX4 expression is notably elevated in resistant tumor phenotypes, including cisplatin-resistant oral squamous cell carcinoma (OSCC) and recurrent nasopharyngeal carcinoma (NPC) [22,45].